SILVER SPRING, Md. and SALZBURG, Austria, Nov. 28, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today that its partner gave a presentation at the 40th Annual Conference of the Austrian Diabetes Society (ÖDG) based on the successful animal model studies for treating diabetes using the Company's proprietary cell encapsulation technology.
The three day event held in November at the Salzburg Congress Center in Salzburg, Austria, hosted an international group of researchers working on treatments for diabetes. Dr. Eva Brandtner, our partner who made the presentation at the meeting, is presently working at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) located in Feldkirch, Austria. She continues to maintain close ties to and is collaborating with Austrianova Singapore (ASPL) and Nuvilex to help advance the diabetes treatment. Dr. Brandtner, formerly Chief Scientist at ASPL before moving back to her native Austria, presented the study data on the use of pancreatic islet cells encapsulated using the Company's proprietary technology for the treatment of diabetes that was completed when she was working at ASPL.
Dr. Brian Salmons, CEO of ASPL said, "We are pleased Dr. Brandtner was invited to give a presentation at this prestigious event. She is a recognized expert in this field and we are very excited to be able to continue working together with Dr. Brandtner and VIVIT to develop new treatments for diabetes."
The Chief Executive of Nuvilex, Dr. Robert Ryan, stated: "Dr. Brandtner's presentation at this important diabetes event in Austria underscores our commitment to novel cell encapsulation based treatments for diabetes. The market potential for such a therapeutic is enormous, still growing dramatically worldwide, and we see the value for patients as priceless."
Nuvilex, Inc. (OTCQB:NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Important advances are moving Nuvilex and Austrianova Singapore forward. New developments by our companies will be substantial as we have been working on many fronts to move us forward. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.
The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494
Safe Harbor Statement
This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 email@example.com